Khiron Announces Completion Of Ibague Colombia Facility

Khiron Life Sciences Corp (OTCMKTS:KHRNF) has announced the completion of construction and the start of operations for growing, extraction and processing in the Ibague Colombia facility. Progress has been made regarding commercial registration as well as the production of medical cannabis products that target over 6 million patients in Latin America .

Milestones and progress made by Khiron

Story continues below

Currently, the company owns and runs one of the most advanced medical cannabis cultivation and production facilities in Latin America. The company has so far completed the development of 14,000 sq ft. state-of-the-art extraction and analysis lab that is ISO 17025 compliant.

The company has also received approval from the Colombian Institute of Agriculture and National Cultivar Registry to list proprietary collection of strains that form a targeted portfolio aimed at addressing major conditions of pain, sleep disorders, and epilepsy. Following the approval, the company is now well-positioned to begin commercial registration, production as well as the distribution of medical cannabis products in Columbia.

The company has commenced the construction of more greenhouses that will complement its initial 80,000 square foot greenhouse. Khiron is well endowed in the Columbian medical cannabis market and it already has established supply and distribution networks for high medical cannabis that is produced from its main facility and it has equally signed an agreement with close to 903 pharmacies across the country and Khiron clinics.

Khiron Life Sciences listed in TSX venture exchange

Khiron Life Sciences has positioned itself for growth to become a dominant cannabis company in Latin America through its cultivation, production, distribution, and export of THC and CBD medical cannabis. Last year the company was listed on the TSX Venture Exchange as part of its global growth and in the process it became the first Colombian medical cannabis company to be listed on any exchange globally.

The company employs a patient-oriented approach and regionally focused strategy through the combination of scientific expertise, branded products, agricultural advantage as well as market experience to drive brand loyalty and prescription to in the Latin America market that is estimated to have more than 620 million people.

An ad to help with our costs